Brief: Coloplast Keeps FY 20204/2025 EBIT Margin Unchanged

Coloplast A/S

14/11/2024 13:25

Nov 14 (Reuters) - Coloplast A/S  COLOb.CO :
    * KERECIS INCLUDED ON LIST OF COVERED PRODUCTS FOR DIABETIC
FOOT
ULCERS IN FINAL LCD POLICY
    * FINANCIAL ASSUMPTIONS FOR KERECIS WITH A 3-YEAR CAGR OF
AROUND
30% UNTIL 2025/26
    * FY 2024/25 EBIT BEFORE SPECIAL ITEMS MARGIN GUIDANCE OF
AROUND
28% IS UNCHANGED

Source text:  ID:nGNE4Zl8nM 
Further company coverage:  COLOb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))